Maxcyte, Inc.
MXCT- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001287098
No open-market purchases or sales by Maxcyte, Inc. insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $78.0M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Maxcyte, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +6 vs. Q2 2022
- Shares held
- 69.9M
- +1.57M (+2.3%) vs. Q2 2022
- Total value
- $453.8M
- +$131.1M (+40.6%) vs. Q2 2022
- New holders
- 18
- 38 more added
- Sold out
- 12
- 29 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MXCT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 122 | $78.0M |
| Q1 2026 | 132 | $46.2M |
| Q4 2025 | 112 | $98.0M |
| Q3 2025 | 112 | $110.8M |
| Q2 2025 | 120 | $155.5M |
| Q1 2025 | 115 | $193.8M |
| Q4 2024 | 119 | $301.9M |
| Q3 2024 | 120 | $267.4M |
| Q2 2024 | 114 | $268.0M |
| Q1 2024 | 124 | $280.8M |
| Q4 2023 | 121 | $316.1M |
| Q3 2023 | 120 | $200.8M |
| Q2 2023 | 116 | $303.3M |
| Q1 2023 | 115 | $327.9M |
| Q4 2022 | 105 | $377.7M |
| Q3 2022 | 109 | $453.8M |
| Q2 2022 | 104 | $322.7M |
| Q1 2022 | 99 | $479.8M |
| Q4 2021 | 104 | $683.6M |
| Q3 2021 | 81 | $665.4M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Maxcyte, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ArrowMark Colorado Holdings LLC | 2,228,099 | $14.5M | 0.18% | +73,862+3.4% | Added |
| Bamco Inc | 2,267,949 | $14.7M | 0.05% | −123,209−5.2% | Reduced |
| Massachusetts Financial Services Co | 2,542,463 | $16.5M | 0.01% | +174,625+7.4% | Added |
| Holocene Advisors, LP | 3,041,960 | $19.8M | 0.13% | 00.0% | Unchanged |
| Blue Water Life Science Advisors, LLC | 3,225,000 | $21.0M | 8.46% | +3,225,000 | New |
| Vanguard Group Inc | 4,665,320 | $30.3M | 0.00% | +1,269,810+37.4% | Added |
| Vitruvian Partners LLP | 5,043,356 | $32.8M | 5.85% | 00.0% | Unchanged |
| BlackRock Inc. | 6,447,943 | $41.9M | 0.00% | +784,524+13.9% | Added |
| Casdin Capital, LLC | 10,735,786 | $69.8M | 4.61% | −3,235,548−23.2% | Reduced |
| RTW Investments, LP | 0 | $0 | 0.00% | −772,735−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −257,068−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −64,500−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −56,294−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −24,000−100.0% | Sold out |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −25,169−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −20,930−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −16,080−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −5,782−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −4,071−100.0% | Sold out |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −1,518−100.0% | Sold out |
| Exane Derivatives | – | – | – | – | Not filed |